Enjoy complimentary customisation on priority with our Enterprise License!
The infectious disease market size is estimated to grow at a CAGR of 12.49% between 2022 and 2027. The infectious disease market size is forecast to increase by USD 104.81 billion. This report covers several market vendors, including Rad Laboratories Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Genetic Signatures Ltd., Grifols SA, Hologic Inc., Meridian Bioscience Inc., Meril Life Sciences Pvt. Ltd., OraSure Technologies Inc., PerkinElmer Inc., QIAGEN NV, Siemens AG, Sysmex Corp., Trinity Biotech Plc, Abbott Laboratories, Becton Dickinson and Co., bioMerieux SA, DiaSorin SpA, Quidel Corp., and Thermo Fisher Scientific Inc. The growth of the market depends on several factors, including the rising demand from the oil and gas industry, the increasing number of applications in food and beverages, and advancements in carbon capturing and storage technologies.
To learn more about this report, View Report Sample
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
bio-rad.com - The company offers therapeutics for infectious diseases that help in earlier diagnosis, appropriate therapy selection, personalized care, and infectious disease monitoring.
The market share growth by the drugs segment will be significant during the forecast period. As per the WHO 2019 Global Tuberculosis Report, the total number of TB-infected patients across the world was estimated to be 6.3 million. The figure fell to 4.9 million in 2020. Fewer cases of TB were notified in 2020 owing to the outbreak of the COVID-19 pandemic, which, in turn, led to over half a million deaths from the disease globally in 2020. Thus, the rising number of cases of infectious diseases is expected to increase the demand for respective drugs, thereby driving the growth of the market during the forecast period.
Get a glance at the market contribution of various segments View PDF Sample
The Drugs segment showed a gradual increase in market share with USD 41.48 billion in 2017 and continued to grow by 2021. The drugs used for the treatment of infectious diseases act either by inhibiting the spread of an infectious agent or by destroying the infectious agent. Bacteria such as Staphylococcus, Streptococcus, Pseudomonas, E. coli, Clostridium difficile, and Listeria are the most common causes of infections leading to skin infections, tonsillitis, cancer, diarrhea, abdominal pain, and fever. Infections caused by viruses are the common cold, flu, chickenpox, COVID-19, and Ebola. Fungal infections such as thrush affect the oral cavities, while protozoal infections can cause intestinal infections. Hence, anti-infective drugs are required to destroy infectious agents that cause various diseases in human beings, including tuberculosis (TB), sepsis, and smallpox. Furthermore, our report provides a brief analysis of the historical and forecast market share and their segments along with the reasons for growth from 2017 to 2027.
For more insights on the market share of various regions View PDF Sample now!
North America is projected to contribute 42% of market growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in North America is led by the US because of the presence of top players such as Gilead Sciences, Inc., Johnson & Johnson, Pfizer, and AbbVie, which generate high revenue from their leading drugs. In addition, these vendors invest in marketing and patient awareness initiatives. The US is one of the major contributors to the market in the region. This is because of the presence of top players, including Aridis Pharmaceuticals, Entasis Therapeutics, and Merck. The market is expected to have accelerated growth momentum during the forecast period. The major factors driving the market growth include the development and launch of drugs for the treatment of infectious diseases and the proper treatment of the patient population.
The increasing prevalence of infectious diseases is notably driving the market growth, although factors such as the adverse effects of anti-infective drugs may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The infectious disease market analysis report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Infectious Disease Market Customer Landscape
The infectious disease market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Infectious Disease Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.49% |
Market growth 2023-2027 |
$ 104.81 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
11.16 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 42% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Bio Rad Laboratories Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Genetic Signatures Ltd., Grifols SA, Hologic Inc., Meridian Bioscience Inc., Meril Life Sciences Pvt. Ltd., OraSure Technologies Inc., PerkinElmer Inc., QIAGEN NV, Siemens AG, Sysmex Corp., Trinity Biotech Plc, Abbott Laboratories, Becton Dickinson and Co., bioMerieux SA, DiaSorin SpA, Quidel Corp., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.